ReviewNature reviews. Cancer2013
Neuroblastoma: developmental biology, cancer genomics and immunotherapy.
Review in Nature reviews. Cancer, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 484 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
484 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Research status and development trends of omics in neuroblastoma a bibliometric and visualization analysis.Frontiers in oncology · 2024Pooled it
- Trial
- Fcγ Receptor Polymorphism in Patients with Relapsed/Refractory High-Risk Neuroblastoma Correlates with Outcomes in the SIOPEN Dinutuximab Beta Long-Term Infusion Trial.Clinical cancer research : an official journal of the American Association for Cancer Research · 2025Trial
- Review
- Amphiphilic Semisynthetic Triterpenoids Impair Survival Pathways and Suppress Clonogenic Growth in Multidrug-Resistant High-Risk Neuroblastoma.International journal of molecular sciences · 2026Article
- Inherent tissue homeostasis of the juvenile metaphysis provides a foundation for osteosarcoma development.Nature communications · 2026Article
- Electrical stimulation induces differentiation onset consistent with a therapeutic approach in neuroblastoma cells.Scientific reports · 2026Article
- Multi‑omics identification of MSI2 as a super-enhancer‑driven vulnerability in MYCN‑amplified neuroblastoma.Journal of translational medicine · 2026Article
- Exploratory Analysis of Tannic Acid-Induced Antiproliferative Effects in SH-SY5Y Neuroblastoma Cells: Associations with Toll-like Receptors and microRNAs.Biomedicines · 2026Article
- Quaternary Phosphonium Salts Outperformed Vemurafenib (PLX) and Etoposide Against BRAFInternational journal of molecular sciences · 2026Article
- Tumor Microenvironment in Neuroblastoma and Immunotherapeutic Approaches: Towards More Effective Treatment.Cancers · 2026Review
- Lactylation-related gene signature as a prognostic biomarker for neuroblastoma: insights into tumor progression and immune modulation.Cell & bioscience · 2026Article
- CD200 expression predicts poor prognosis in neuroblastoma: a potential biomarker for treatment stratification-a retrospective cohort study.Pediatric surgery international · 2026Article
- VLX1570 suppresses neuroblastoma growth through inhibition of PCNA-associated proliferative signaling and potentiates cisplatin antitumor activity.Frontiers in pharmacology · 2026Article
- Integrative precision oncology in neuroblastoma: multi-omics biomarkers, molecular targets, and immunotherapeutic strategies.Frontiers in oncology · 2026Review
- Metabolomics-guided identification of bioactive phytometabolites from South African plants targeting neuroblastoma.Experimental biology and medicine (Maywood, N.J.) · 2026Article
- Regulatory Relationships between DNA Methylation and Long Noncoding RNAs in Neuroblastoma.Current medicinal chemistry · 2026Review
- [European journal of nuclear medicine and molecular imaging · 2026Observational
- Investigating the Role of Membrane Environment in the Recognition of GD2 Ganglioside with Antibodies.Doklady. Biochemistry and biophysics · 2025Article
- Temporal trends in cross-country inequalities of neuroblastoma burden in children under 14 years of age from 1990 to 2021.Translational pediatrics · 2025Article
424 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Neuroblastoma is a solid tumour that arises from the developing sympathetic nervous system. Over the past decade, our understanding of this disease has advanced tremendously. The future challenge is to apply the knowledge gained to developing risk-based therapies and, ultimately, improving outcome. In this Review we discuss the key discoveries in the developmental biology, molecular genetics and immunology of neuroblastoma, as well as new translational tools for bringing these promising scientific advances into the clinic.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.